Investigating biomarkers in ovarian cancer
Prognostic and Predictive Biomarkers in Ovarian Cancers
NA · Gustave Roussy, Cancer Campus, Grand Paris · NCT03010124
This study is trying to find specific markers in ovarian cancer patients' samples to see how they relate to treatment success and to improve personalized treatment options.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Villejuif, Val de Marne) |
| Trial ID | NCT03010124 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze tumor samples, ascites, blood, and other biological materials from patients with ovarian cancer to identify prognostic and predictive biomarkers. By correlating these markers with patient outcomes, the research seeks to understand how genetic diversity in ovarian cancer affects chemotherapy resistance. Additionally, the study will perform functional assays on freshly collected samples to validate potential therapeutic targets. The goal is to enhance treatment strategies based on individual patient profiles.
Who should consider this trial
Good fit: Ideal candidates include new patients diagnosed with ovarian cancer or previously treated patients with available tumor samples who are experiencing disease progression.
Not a fit: Patients who do not meet the inclusion criteria or those with coagulation abnormalities that prevent biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for ovarian cancer patients.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for ovarian cancer, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. New patient with a diagnosis of OC, or 2. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center presenting with progressive disease, and consenting to CT guided biopsy of relapsed disease, or 3. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center scheduled for surgery for relapsed disease. 4. Signed informed consent 5. Age ≥ 18 6. Patient affiliated to a social security regimen or beneficiary of the same Exclusion Criteria: 1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral treatment; 2. Coagulation abnormalities that contra-indicates the biopsy
Where this trial is running
Villejuif, Val de Marne
- Gustave Roussy — Villejuif, Val de Marne, France (RECRUITING)
Study contacts
- Study coordinator: Alexandra LEARY, MD
- Email: alexandra.leary@gustaveroussy.fr
- Phone: +33 (0)1 42 11 43 89
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ovarian Cancer